Im Focus Onkologie

, Volume 20, Issue 6, pp 34–37 | Cite as

Ursachen und Behandlungskonzepte

Kognitive Dysfunktionen bei Krebspatienten

Fortbildung

Eine kognitive Dysfunktion (KD) in Form von Konzentrations- und Gedächtnisstörungen wird bei Krebspatienten häufig beobachtet. Besonders intensiv untersucht wurden in dieser Hinsicht Frauen nach einer Brustkrebserkrankung. Bei ihnen fanden sich hohe Raten von KD. Erst in den letzten Jahren wurde dieser relevanten Funktionsstörung mehr Bedeutung beigemessen.

Literatur

  1. 1.
    Cheung YT et al. Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. Crit Rev Oncol Hematol. 2012;83(1):99–111.CrossRefPubMedGoogle Scholar
  2. 2.
    Schagen SB et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98(23):1742–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012;12(3):267–75.CrossRefPubMedGoogle Scholar
  4. 4.
    Vardy J et al. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol. 2007;25(17):2455–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Bender CM, Thelen BD. Cancer and cognitive changes: the complexity of the problem. Semin Oncol Nurs. 2013;29(4):232–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Mehnert A et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns. 2007;66(1):108–18.CrossRefPubMedGoogle Scholar
  7. 7.
    Myers JS. Cancer- and chemotherapy-related cognitive changes: the patient experience. Semin Oncol Nurs. 2013;29(4):300–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Janelsins MC et al. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol. 2017;35(5):506–14.CrossRefGoogle Scholar
  9. 9.
    Vardy JL et al. Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol. 2015;33(34):4085–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Rick O et al. NeuroCog-FX Study: A Multicenter Cohort Study on Cognitive Dysfunction in Patients with Early Breast Cancer. Ann Oncol. 2017, submitted.Google Scholar
  11. 11.
    Scherwath A et al. Psychometric evaluation of a neuropsychological test battery measuring cognitive dysfunction in cancer patients—recommendations for a screening tool. Fortschr Neurol Psychiatr. 2008;76(10):583–93.CrossRefPubMedGoogle Scholar
  12. 12.
    Hoppe C et al. NeuroCog FX: computerized screening of cognitive functions in patients with epilepsy. Epilepsy Behav. 2009;16(2):298–310.CrossRefPubMedGoogle Scholar
  13. 13.
    Hermelink K et al. Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst. 2015;107(7). pii: djv099.CrossRefPubMedGoogle Scholar
  14. 14.
    Schagen SB et al. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology. 2012;21(10):1132–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Deprez S et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Ferguson RJ et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866–70.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kesler SR et al. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447–53.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    de Ruiter MB et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamada TH et al. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci. 2010;22(1):48–54.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ahles TA. Brain vulnerability to chemotherapy toxicities. Psychooncology. 2012;21(11):1141–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mehlsen M et al. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology. 2009;18(3):248–57.CrossRefPubMedGoogle Scholar
  22. 22.
    Chan RJ et al. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer. 2015;51(4):437–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Bray VJ et al. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol. 2017;35(2):217–225.CrossRefPubMedGoogle Scholar
  24. 24.
    Damholdt MF et al. Web-based cognitive training for breast cancer survivors with cognitive complaints-a randomized controlled trial. Psychooncology. 2016;25(11):1293–1300.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kesler S et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer. 2013;13(4):299–306.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Conklin HM et al. Computerized Cognitive Training for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors: A Randomized Controlled Trial. J Clin Oncol. 2015;33(33):3894–902.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hines S et al. The effectiveness of psychosocial interventions for cognitive dysfunction in cancer patients who have received chemotherapy: a systematic review. Worldviews Evid Based Nurs. 2014;11(3):187–93.CrossRefPubMedGoogle Scholar
  28. 28.
    Vadiraja SH et al. Effects of yoga on symptom management in breast cancer patients: A randomized controlled trial. Int J Yoga. 2009;2(2):73–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Milbury K et al. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology. 2013;22(10):2354–63.PubMedGoogle Scholar
  30. 30.
    Oh B et al. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer. 2012;20(6):1235–42.CrossRefPubMedGoogle Scholar
  31. 31.
    Johns SA et al. Randomized controlled pilot trial of mindfulness-based stress reduction for breast and colorectal cancer survivors: effects on cancer-related cognitive impairment. J Cancer Surviv. 2016;10(3):437–48.CrossRefPubMedGoogle Scholar
  32. 32.
    Fardell JE et al. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl). 2012;220(1):183–93.CrossRefGoogle Scholar
  33. 33.
    Miki E et al. Feasibility and efficacy of speed-feedback therapy with a bicycle ergometer on cognitive function in elderly cancer patients in Japan. Psychooncology. 2014;23(8):906–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin 2017

Authors and Affiliations

  1. 1.Klinik ReinhardshöheBad WildungenDeutschland

Personalised recommendations